Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: Current Status and Future Prospects by Om Prakash Singh & Shyam Sundar
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 26 June 2014
doi: 10.3389/fimmu.2014.00296
Immunotherapy and targeted therapies in treatment of
visceral leishmaniasis: current status and future prospects
Om Prakash Singh and Shyam Sundar*
Infectious Disease Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India
Edited by:
Nahid Ali, Indian Institute of Chemical
Biology, India
Reviewed by:
Scott D. Gray-Owen, University of
Toronto, Canada
Lynn Soong, The University of Texas
Medical Branch, USA
*Correspondence:
Shyam Sundar , Infectious Disease
Research Laboratory, Department of
Medicine, Institute of Medical
Sciences, Banaras Hindu University,
Varanasi, Uttar Pradesh 221005, India
e-mail: drshyamsundar@hotmail.com
Visceral leishmaniasis (VL) is a vector-borne chronic infectious disease caused by the pro-
tozoan parasite Leishmania donovani or Leishmania infantum. VL is a serious public health
problem, causing high morbidity and mortality in the developing world with an estimated
0.2–0.4 million new cases each year. In the absence of a vaccine, chemotherapy remains the
favored option for disease control, but is limited by a narrow therapeutic index, significant
toxicities, and frequently acquired resistance. Improved understanding of VL pathogen-
esis offers the development and deployment of immune based treatment options either
alone or in combination with chemotherapy. Modulations of host immune response include
the inhibition of molecular pathways that are crucial for parasite growth and maintenance;
and stimulation of host effectors immune responses that restore the impaired effector
functions. In this review, we highlight the challenges in treatment of VL with a particular
emphasis on immunotherapy and targeted therapies to improve clinical outcomes.
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INTRODUCTION
Leishmaniasis , a spectrum of diseases caused by Leishmania
species, affects ~12 million people around the world, mostly in
developing countries. It is transmitted by sand flies (Phlebotomus
species) as extracellular flagellated promastigotes and replicate as
intracellular, aflagellated amastigotes in mononuclear phagocytes
in mammalian host (1). Depending on the species, the disease
symptoms may range from self-healing skin lesions to the fatal
visceral form known as kala-azar or visceral leishmaniasis (VL).
Kala-azar is the most severe form of the leishmaniasis and accounts
for 200–400 thousands new cases and over 50,000 deaths annually
(2). Anthroponotic transmission of VL is caused by Leishmania
donovani and prevails in Indian subcontinent and East Africa;
while zoonotic transmission of VL is caused by L. infantum (syn. L.
chagasi) in the Mediterranean region, South America, and South-
west and Central Asia. The majority of all cases (90%) are found
in India, Nepal, Bangladesh, Brazil, South Sudan, and Ethiopia
(3), where transmission typically occurs from humans infected
with kala-azar or post kala-azar dermal leishmaniasis (PKDL) (4,
5). More specifically, an estimated 80% of the global burden of
VL occurs in South Asia (e.g. in 2007, 100,000–150,000 of the
cases occurred in India alone). The situation is especially severe in
Bihar State in eastern India, where some districts have faced the
worst epidemic since the 1970s. Left untreated, VL is fatal, and the
burden of disease expressed in disability-adjusted life years is esti-
mated to be ~2.5 million. Furthermore, over 90% of all individuals
with VL earn an income of <2 United States (US) dollars per day.
Because VL is associated with resource-poor regions, access to care
is another challenge in the overall management and treatment of
VL (6, 7). The situation is further complicated by the emergence
of resistant strains to currently available anti-leishmanial drugs
and by the limited availability of inexpensive, non-toxic drugs
(Table 1). Antimonial chemotherapy has been the mainstay for
VL treatment for more than 50 years, and continues to be the
recommended first line treatment in most parts of the world (8).
Resistance to pentavalent antimonials (Sbv) has first been reported
in northern Bihar, where nearly 60% of individuals are now unre-
sponsive to this drug (9). Pentamidine has been the second line
drug used in Sbv refractory patients. Unfortunately, its efficacy has
also declined over the years, and now curing only ~70% patients.
Resistance has also been reported with pentamidine and milte-
fosine (10, 11), and there is growing concern for resistance with
paromomycin monotherapy (12). Increasing parasite drug resis-
tance, longer treatment times, and associated toxicity to patients
has resulted in the need to use more expensive drugs such as AmBi-
some® (liposomal amphotericin B) and miltefosine (8). A recent
study demonstrated a single dose of liposomal amphotericin B is
an effective VL treatment (13). However, concerns about emerging
drug resistance with single drug therapy have led to testing liposo-
mal amphotericin B in combination with oral miltefosine (14, 15).
This strategy is still requiring administration of the drugs over an
extended period and cost and toxic side effects are major issues.
Hence, dose-sparing strategies that shorten treatment times are
likely to be of major benefit to VL treatment programs. In addi-
tion, an intervention that can reduce the risk of developing PKDL
is also highly desired. Importantly and relevant to this discus-
sion, drug therapy works most effectively with help from the host
immune system, and in particular, cell mediated immune (CMI)
responses. Hence, immune modulation that stimulates immunity
and work synergistically with drugs has enormous potential for
drug-sparing strategies that would help in the treatment of a broad
range of diseases.
Currently, there is no effective human vaccine available for
any form of leishmaniasis. One of the major challenges in vac-
cine development has been a limited understanding of the precise
immune mechanisms required for controlling parasite growth
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Table 1 | Current VL treatments with anti-leishmanial drugs: their mode(s) of action on parasites, dosage, efficacy, advantages and limitations.
Drugs Mode(s) of action Dosage Efficacy (%) Advantages Limitations Reference
1 Pentavalent
antimonials:
sodium
stibogluconate
(Pentostam) or
meglumine
antimoniate
(Glucantime)
Acts as pro-drug that is
converted to active and more
toxic trivalent form within the
amastigote/macrophage; and
this active trivalent SbIII form
inhibits trypanothione
reductase and exposes
parasite to oxidative stress of
the host
20 mg/kg/day
(i.m.) for
20–30 days in
India
80–90 (50% in
Bihar, India)
Low cost and
easily availability
in endemic area
Pancreatitis, cardiac
arrhythmias,
acquired resistance
in the Indian
subcontinent
(8, 16, 17)
2 Amphotericin B
(Fungizone)
Form complexes and bind to
ergosterol in parasite
membranes that create
pores, which alter ion
balance, increase membrane
permeability resulting in cell
death; also acts as an inhibitor
of ergosterol biosynthesis
0.75–1.0 mg/kg
for 15–20
infusions either
daily on alternate
days in India (i.v)
>95% Effective in
antimony
resistant regions,
primary
resistance is
unknown
High cost and need
of prolonged
hospitalization, rigor,
and fever with renal
complications,
hypokalemia
(16, 18, 19)
3 Liposomal
amphotericin B
(AmBisome)
Targeted delivery of drug to
the infected macrophage and
mechanism of action is same
as amphotericin
3.0 mg/kg/day for
5 days (total
15 mg) OR
10 mg/kg as a
single dose, i.v
>96% Highly effective,
low toxicity,
resistance is not
documented
High cost (13)
4 Paromomycin
(aminoglycoside
antibiotic), also
known as
aminosidine
Exact mechanism is not
known. In bacteria, inhibits
protein synthesis, but in
Leishmania, it decreases the
mitochondrial membrane
potential of L. donovani
promastigotes
11 mg/kg of
base/day for
21 days (i.m.)
95% Acts
synergistically
with antimonials,
effective, well
tolerated, and
cheapest drug for
VL
Reversible
ototoxicity but no
nephrotoxicity, lack
of efficacy in East
Africa
(20–22)
5 Miltefosine Interacts with the cell
membrane of Leishmania
parasites by modulation of
cell surface receptors, inositol
metabolism, and
phospholipase activation, Cell
death being mediated by
apoptosis
50 mg/day for
adults <25 kg and
100 mg/day
>50 kg adults
(oral)
85–95% First oral drug for
VL. Currently first
line of treatment
in Indian
subcontinent
Potentially
teratogenic,
vomiting, and
diarrhea with
occasional hepatic
and renal toxicity
(15, 19)
6 Pentamidine Accumulate in parasite
mitochondria and inhibit
mitochondrial topoisomerase
II, binding to AT-rich sites in
the minor groove of DNA
followed by inhibition of
transcription process
4 mg/kg/day for
three times
weekly for 15–20
dose (i.m or i.v)
70–80% Low efficacy,
toxic. May be
used in
combination with
other drugs
Gastrointestinal side
effects, cardiac,
arrhythmias,
hypotension,
pancreatitis, and
irreversible
insulin-dependent
diabetes mellitus
(23, 24)
(25, 26). In the present review, we highlight the current sta-
tus and challenges in treatment of leishmaniasis with focus
on immune based strategy for improving treatment regimens
for VL.
IMMUNE REGULATION AND IMMUNOPATHOGENESIS
Mammals have evolved to recognize and control pathogens,
including the recognition of infected cells. This is achieved by the
coordinated actions of innate and adaptive immune mechanisms
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[reviewed in Ref. (27)]. The innate immune response involves
the recognition and early control of threats to the body as well
as for the activation of adaptive immunity. Adaptive immune
response involves B cells that produce specific antibodies; and T
cells that recognize peptide antigens. T cell responses are mediated
by CD8+ T cells that recognize peptides derived from both inside
and outside of cells and presented by major histocompatibility
class (MHC) I molecules on the cell surface or CD4+ T cells that
recognize peptides from microbes or antigens engulfed by pro-
fessional phagocytes and then presented on the context of MHC
II molecules. The main targets of immunomodulatory strategies
should be CD4+ T cells because they play critical roles in coor-
dinating immune responses by producing molecules critical for
the production of high affinity antibodies by B cells, essential for
activation of CD8+ T cells to kill infected and transformed cells.
Based on the studies in the L. major/BALB/c mouse model,
the immune dysregulation associated with non-healing and dis-
seminating forms of leishmaniasis has been associated with a
parasite-driven Th2 polarized response, in which interleukin (IL)-
4 is especially dominant [reviewed in Ref. (28)]. Accumulating data
in human VL, however, indicate that the cytokine responses are
not highly polarized, and even during the acute phase of disease,
elevated levels of interferon-γ (IFN-γ) mRNA have been found
in lesional tissue, such as the spleen and bone marrow (29–31).
Furthermore, in human VL, overproduction of IL-10 provides a
much better correlate of susceptibility than IL-4. The vast array
of cytokines, chemokines, and immune mechanisms involved in
the host immune response to Leishmania clearly highlights the
complexity of diseases (32, 33). Based on studies in mice, produc-
tion of interleukin-12 (IL-12) by antigen-presenting cells (APCs)
and IFN-γ by T cells appear to be required for the control of the
parasites and development of acquired resistance (34, 35). IL-12
is regulatory cytokine for initiation and maintenance of the Th1
response and plays an important role in the induction of IFN-
γ production by T and NK cells (36–40). Priming of susceptible
BALB/c mice with exogenous rIL-12 during Leishmania infection
also promotes protection and gives self-healing phenotype (41,
42). On the other hand, Leishmania parasites have been shown
to inhibit IL-12 production, resulting in decreased leishmanicidal
activity of macrophage (43). Maintenance of the proportion of
CD4+ and CD8+ T cells required for cytokines secretion is the
crucial step in generation of immunity against leishmaniasis. In
active VL, both CD4 and CD8 cells are activated and play distinct
but cooperative role in disease resolution. CD4+ cells play a role
in the control of primary infection, while CD8+ cells are thought
to be more important during secondary immune response (44).
Human VL is characterized by very high titers of Leishmania-
specific antibodies, appearing soon after infection but before the
development of cellular immunological abnormalities (45, 46).
These anti-leishmanial antibodies persist up to 16 years after treat-
ment, suggesting its possible involvement in immunity (47). There
are reports that B cells and antibodies correlate with pathology,
but role of these antibodies in disease resolution or protection is
unknown. Studies have also shown that animals lacking B cells
are resistant to Leishmania infections (48), but such evidence on
human VL are still lacking. Importantly, in endemic area of Bihar
(India), strong association were found between seropositivity and
progression to clinical diseases in healthy individual (49), suggest-
ing its role in disease pathogenesis. Therefore, in-depth studies
are required before any conclusion can be drawn. More recently,
we have reported high anti-leishmanial antibodies in Indian VL
patients compared to Sudanese patients and could be one of the
factor for lower sensitivity of serological tests in East Africa (50).
Most importantly, anti-leishmanial antibodies do not play any role
in antigen-specific IFN-γ or IL-10 production in whole blood of
active VL patients (unpublished data).
TARGETED THERAPY AND IMMUNOTHERAPY
In the absence of human vaccine and effective vector control mea-
sures, chemotherapy is the only option for treatment and control
of VL. Several hundred comparative and prospective cohort stud-
ies on therapies for leishmaniasis have been published (Table 1).
Increasing evidence of drug unresponsiveness and resistance has
raised concern to save the drugs, as the armory of anti-leishmanial
drugs is limited. Reports of emerging resistance to Miltefosine, the
newest and only oral anti-leishmanial drugs, which is the basis
of VL elimination program, are particularly worrying (14); and
makes VL management and elimination challenging. Drug discov-
ery is struggling to prevent resistance, therefore changes in the drug
policy are much needed step as on today. Reductions in VL mor-
bidity and mortality will require the development and deployment
of immune modulators in order to achieve the prophylactic or
therapeutic goal; and also prevent the transmission of Leishmania
from human to sand fly. One of the most interesting approaches
currently being explored is immunotherapy and targeted therapy
[reviewed in Ref. (51)]. Targeted therapies act by blocking essen-
tial biochemical or signaling pathways that are indispensable for
Leishmania parasite growth and survival, however, immunother-
apy involves the use of biological molecules or compounds to
modulate immune responses in combination with drugs. Over the
last two decades, various approaches of immunotherapies or tar-
geted therapies have been developed and applied in the treatment
of human leishmaniasis (Table 2). The strengths and weaknesses
of such therapies suggest that both approaches might have com-
plimentary roles in VL treatment, and combination could prove
synergistic. Because targeted therapies can induce rapid parasite
clearance, with a consequent decrease in Leishmania associated
immune-suppression, they might afford a favorable window for
immunotherapy to improve the efficacy of treatment.
TARGETING HOST IMMUNITY BY ANTI-LEISHMANIAL
DRUGS/MOLECULES
Within the mammalian host, parasites reside as amastigotes in
phagocytic cells such as polymorphonuclear neutrophils (PMN),
macrophages, and dendritic cells (DCs). Therefore, it is important
to identify an immunomodulatory compound with leishmanici-
dal properties capable of activating phagocytic cells. Following
entry of Leishmania parasite into the mammalian host, PMNs are
thought to be the first effector cells recruited to the site of infec-
tion within 24 h, implying that they possibly serve as host cells
for Leishmania parasites in the very early phase of infection (67).
Neutrophils being inherently short-lived and apoptotic, are usually
cleared without triggering activation of macrophages (67), while
Leishmania parasites are known to delay neutrophils apoptosis,
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Table 2 | Immunotherapy of human leishmaniasis.
Country Year Immunotherapeutic agent Chemotherapeutic No. of Disease/ Treatment Reference
agent patients parasite efficacy
India 1995 IFN-γ Sbv 16 VL 87% (52)
Brazil 1990 IFN-γ Sbv 17 VL 82.3% (53)
Brazil 2005 GM-CSF Sbv 05 CL 100% Cure (54)
Brazil 2006 Killed L. amazonensis+BCG Glucantime 47 ACL 87% (55)
Brazil 2006 Mixed antigensa – 06 MCL 76–94% (56)
Brazil 2002 Killed L. amazonensis Meglumine 47 ACL 100% (57)
Argentina 2011 Killed L. amazonensis+BCG – 01 ACL High (58)
Peru 2007 Imiquimod Sbv 07 CL 72% (59)
Kenya 1993 IFN-γ Sbv 10 VL 75% (60)
Sudan 2008 Alum/ALM+BCG Sbv 15 PKDL 87% (61)
Iran 2006 Imiquimod Glucantime 59 CL 44.1% (62)
Uzbekistan 1993 Leukinferon (i.m.) Monomycin 50 CL High (63)
Venezuela 1990–1999 Pasteurized L. braziliensis+BCG – 5341 CL 91.2–98.7% (64)
Venezuela 1994–2000 Mixture antigensb Sbv 87 CL Moderate (65)
Venezuela 2004 Pasteurized L. braziliensis+BCG – 07 MCL, DCL 100% (66)
VL, visceral leishmaniasis; CL, cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis; PKDL, post kala-azar dermal
leishmaniasis; BCG, bacillus Calmette–Guerin; Sb, sodium stiboguconate; IFN-γ, interferon-γ; mixture antigens
a: TSA, thiol-specific antioxidant; LmSTI1, L. major stress inducible protein 1; LeIF, Leishmania elongation initiation factor; Lbhsp83, Leishmania heat shock protein
83; GM-CSF, granulocyte macrophage colony-stimulating factor; mixture antigens
b: amastigotes from L. (L.)amazonensis (La), L. (L.)venezuelensis (Lv), L. (V.)brasiliensis (Lb), and L. (L.)chagasi (Lch) Tosyl-Lysyl Chloromethyl-ketone (TLCK) treated
and Non-idet P-40(NP-40) extracted (VT).
possibly by interfering with production of reactive oxygen species
(ROS) (68, 69). Therefore, it would be logical and important to
search an anti-leishmanial compound capable of generating an
oxidative burst within Leishmania infected neutrophils to effec-
tively eliminate parasites. Berberine chloride has been one of
the compounds recently reported to enhance the apoptosis of L.
donovani-infected neutrophils via modulation of the MAP kinase
pathways (70).
Leishmania parasites that enter into macrophages via the uptake
of infected, apoptotic PMNs may survive and multiply effectively
(67). Since, macrophages have ability to kill parasite upon activa-
tion, Leishmania parasites overcome these macrophage activation
and recognition by creating an anti-inflammatory milieu, bene-
ficial for parasites survival. It has been reported that the amount
of TGF-β secreted by macrophages following uptake of infected
PMNs is higher than after direct uptake of L. major promastig-
otes (67), suggests that uptake of infected, apoptotic PMNs are
responsible for creation of this environment within macrophages.
Therefore, targeting pathogens residing in neutrophils should be
taken into consideration when designing targeted novel anti-
leishmanial compounds, as neutrophils harbor and transport par-
asites. For example, antimonials (sodium stibogluconate) increase
the phagocytic capacity of neutrophils along with increased pro-
duction of superoxide (71), unfortunately the loss of efficacy of
antimonials has occurred in the Indian subcontinent and thus
raised concern to search another compounds. In fact, several
strategies to interfere with macrophage signaling by parasites have
been reported that favor its survival in host cells (72). Oghumu
et al. have highlighted the role of STAT4 pathway in immunity
to L. donovani infection and also reported the evidence that
STAT4 is dispensable for antimonial-based chemotherapy (73).
Furthermore, some of the other strategies employed by Leishma-
nia to evade effector mechanisms of the host immune system are
the recruitment of inhibitory CD4+CD25+FoxP3+ regulatory T
cells (Treg) (74, 75), inhibition of macrophage phagosomal mat-
uration (76), and inhibition of DC maturation (77). Receptors
expressed on Treg or its corresponding ligands on effectors cells,
such as glucocorticoid-induced TNF receptor family-related pro-
tein (GITR), PD-1, it is ligands programed cell death ligand-1
(PD-L1, B7-H1) or cytotoxic T lymphocyte antigen-4 (CTLA-4)
could be also used as potential targets in future studies, as targeting
these regulatory pathways has proven effective in experimental VL
(78, 79).
CYTOKINE IMMUNOTHERAPY
Cytokines are the messengers of the immune system. They have
autocrine and paracrine functions, so that they function locally
or at a distance to suppress or enhance immunity. Attempts to
identify cytokines that selectively induce Th1 responses might be
useful in VL therapy. The evidence of the utility of cytokines as
therapeutic use came from the studies by Murray et al., when
an anti-IL-10 receptor monoclonal antibody (anti-IL-10R mAb)
was reported to inflict parasite killing through an inducible nitric
oxide synthase-dependent mechanism (80). Thus, immunostim-
ulatory cytokines (e.g., IFN-γ, IL-12, GM-CSF) or antibodies that
target suppressive/deactivating cytokines are being investigated or
proposed as monotherapies or as combination therapies with Sbv
or other drugs. Combination therapy with recombinant human
IFN-γ and pentavalent antimonials have been reported as stronger
parasitological and clinical cure; compared with the drug alone in
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VL patients from Brazil, Kenya, and India (53, 60, 81). Short course
of IFN-γ is thought to be sufficient to activate macrophage and
thereby accelerate parasitologic effect of Sbv. IL-12 is another key
cytokine inhibited by Leishmania parasites. Exogenous treatment
with rIL-12 during Leishmania infection leads to resistance in
susceptible mice (41), suggesting its important use in clinical out-
come. However, suppression of other cytokines, including receptor
fusion antagonists of IL-13, IL-4, and TGF-β inhibit parasite repli-
cation but only marginally affect parasite clearance without the
induction of a synergistic effect with pentavalent antimonials (82).
In a study, GM-CSF plus either with meglumine antimonite (54)
or a mixture of L. major antigens (LmSTI1+ LeIf+HSP83) (56),
was reported as being highly effective in treating American CL and
MCL (Table 2).
IL-10: ROLE IN VL PATHOGENESIS AND IMMUNOTHERAPY
Visceral leishmaniasis pathogenesis has been associated to an over-
production of the regulatory cytokine, IL-10, which can promote
parasite replication and disease progression. Several studies per-
formed to characterize the immunologic effects of VL have focused
on the role of IL-10 in the suppression of DC functions and render-
ing macrophages unresponsive to activation signals (83). Experi-
mental models have demonstrated that IL-10 plays a central role
in the pathogenesis and parasite growth in VL, as IL-10-deficient
BALB/c and C57BL6 mice are highly resistant to L. donovani infec-
tion (84). Treatment of L. donovani-infected wild-type mice with
a single dose anti-IL-10R mAb and daily low doses of Sbv resulted
in rapid control of the L. donovani infection and dramatically
enhanced the therapeutic effects of Sbv namely, an over 10-fold
dose-sparing effect was observed with Sbv and a shortened dura-
tion of treatment (85). In a separate study, single dose anti-IL-10R
mAb (0.5 mg) treatment triggered a 63% liver parasite killing in L.
donovani-infected BALB/c mice; moreover, when administered at
a reduced dose (0.1 mg), the anti-IL-10 mAb enhanced the effect of
Sbv, also administered at a suboptimal dose (50 mg/kg), leading to
a 72% liver parasite killing (82). Similar results were observed in L.
donovani-infected BALB/c mice treated with a suboptimal single
dose (0.1 mg) of an anti-IL-10R mAb and low-dose Amphotericin
B (2 mg/kg total dose) (86). The combination therapy induced a
76% liver parasite killing, compared with a 16% observed with the
anti-IL-10R mAb alone.
Elevated levels of IL-10 in serum as well as enhanced IL-10
mRNA expression in lesional tissue during active disease are a
consistent finding in human VL [reviewed in Ref. (87)]. More
recently, we have reported antigen stimulated IL-10 production
in whole blood cells of VL patients and have shown a strong
association of IL-27 and IL-21 with the up-regulation of the
IL-10 response, and revealed the presence of both IFN-γ and
IL-10 producing antigen-specific cells in the peripheral blood of
VL patients (74, 88, 89). The findings have led to an underly-
ing hypothesis that during active disease antigen-specific IL-10
producing T cells are activated under conditions that also drive
strong and persistent Th1 responses, and the balance of these
cells and the cytokines they produce favors the progression of
disease. It has been shown that infected macrophages, Th1, Th2,
CD8+ T cells, and subsets Treg, of which naturally occurring
CD4+CD25+Foxp3+ Treg cells and antigen-inducible or adaptive
Treg are the best defined, are all a potential source of IL-10 capable
of suppressing Leishmania-specific immunity (90–92). Key find-
ings have identified CD4+CD25−Foxp3− or adaptive Treg as the
main source of both elevated IL-10 and IFN-γ in the spleen of
VL patients (74). Furthermore, antigen driven IL-10 production
has been difficult to detect in culture of peripheral blood mononu-
clear cells (PBMCs) (88, 93, 94). These findings are consistent with
reports from a number of studies, which suggest that the immuno-
logic defect in VL is characterized not by the complete absence
of a potentially curative type 1 immune response, but by the
co-expression of suppressive cytokines that compromise the leish-
manicidal function and potency of the effector response in target
organs, such as the spleen. A direct role for IL-10 in the pathology
of VL is supported by studies demonstrating that IL-10 block-
ade can enhance IFN-γ responses (29, 95). More recently, we have
demonstrated anti-parasitic effect of IL-10 blockade in human VL,
showing that neutralization of IL-10 results in marked reduction
of parasite number present in splenic aspirate cells (89). In con-
tinuation with these ex vivo supporting findings, Phase I study of
anti-IL-10 mAb alone and in combination with AmBisome have
been recently proposed for the human trial (clinicaltrial.gov) and
this combination is expected to induce synergistic effects that con-
tain the VL infection and immunopathology associated with the
disease, while overcoming the threat of drug resistance and possi-
bly achieving a chemotherapeutic dose-sparing effect that results
in better efficacy and adherence to treatment. Importantly,demon-
strating a therapeutic benefit from the IL-10 neutralization as a
proof of concept will open the door to other strategies targeting
the inhibition of IL-10 and other immunosuppressive factors.
DENDRITIC CELL-BASED IMMUNOTHERAPY
Another novel approach is the application of DCs for the induction
of antigen-specific T cell immunity. The interaction of DCs and
Leishmania parasites are complex and thought to be responsible
for control of infection or progression of clinical disease (96). DCs
play an important role in initial anti-Leishmania T cell responses
and promoting their differentiation into memory T cell to achieve
long lasting immunity, which makes them attractive candidates for
potential synergy with immunotherapy [reviewed in Ref. (51)].
Interestingly, a C-type lectin receptor, DC-SIGN (DC-specific
ICAM-3-grabbing non-integrin), which is exclusively expressed
on tissue monocyte-derived DCs, has been shown to favor par-
asite survival by binding with distinct Leishmania species. It is
then suggested that this receptor could also be taken into con-
sideration as therapeutic target for both visceral and cutaneous
leishmaniasis (97).
Dendritic cells based immunotherapy combined with
antimony-based chemotherapy has been shown very effective
against murine VL (98). Bone marrow derived DCs pulsed with
soluble L. donovani antigen when given in combination with
antimonials has been shown to reduce both hepatic and splenic
parasite burden significantly (51). Thus, the future of DC-based
immunotherapy appears promising and it could be looked upon
as a prospective vaccine against VL.
CHALLENGES AND FUTURE DIRECTIONS
Treatments that enhance immune responses to fight against dis-
eases are of significant clinical interest. A possible approach to
overcome some of the challenges associated with the management
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and treatment of VL is the use of immune based combination
therapy (99), which has been proven successful in other parasitic
diseases, such as malaria, tuberculosis, and leprosy (100). A com-
bination of drugs with different modes of action could eliminate
the potential for drug resistance and induce a chemotherapeutic
dose-sparing effect, since the mechanism for resistance would be
different for each drug (100). One drug could target the para-
site itself, while a second drug or compound could modulate the
immune system of the host (101–103). Likewise, the combination
of drugs with different half-lives could provide a synergistic effect
in the timing and exposure of the parasite to the different drug
levels (100, 103).
Although, considerable progress on VL treatment has been
made over the past years, we still have a limited understanding
of the precise immune mechanism underlying human VL. One of
the major problems in translating discoveries from disease models
into treatments for humans is the risk that potential treatment
strategies do not work on human cells in the same way as they do
in the experimental model. Second and most important key issue
for immunotherapy or targeted therapies is whether intensified
anti-Leishmanial effects can be achieved without a corresponding
increase in serious toxicities, as immunomodulatory agents that
provoke an immune response may also pose a risk of severe sensi-
tization, which might be anticipated to increase allergic reactions
and lead to reduction in treatment efficacy.
Cytokine (e.g., IL-10) has therapeutically been used as a recom-
binant protein (i.e., a large molecule), which is quite expensive to
produce. It can be only administered by injection, which is also
quite inconvenient for the patient. It will then be important to
ensure that the cost associated with cytokine immunotherapy must
be less than conventional treatment and reach to the populations
that need it most. Another better approaches could be to target
the molecules acting downstream of the cytokine receptors or sig-
nal transduction. The problems in such cases are the specificity,
as the known cytokine signaling pathways are shared by different
cytokines. Therefore, problems and side effects associated with the
use of cytokine therapy have to be addressed properly before its
clinical application.
Although, these observations strongly support immunotherapy
as a promising alternative to conventional chemotherapy against
VL, big challenge remains to ensure long term maintenance of
response and safety of treatments with biologic agents.
CONCLUSION
Each VL patients represents our failure to prevent leishmaniasis,
and each death represents our failure to treat soon enough. Until
VL elimination has been achieved, drug treatment will remain
crucial to prevent complications and death from VL. There is
an urgent need for innovative and effective alternative thera-
pies against VL. Understanding of crucial cellular pathways that
promote Leishmania parasite growth and maintenance together
with the development of compounds or agents that specifically
inhibit these pathways has offered a new era for anti-leishmanial
therapy. The use of immunotherapy and targeted therapy could aid
in addressing some of the current challenges associated with the
management and treatment of VL, namely, minimizing resistance
to currently available drugs, improving the therapeutic index,
decreasing the dose or length of treatment, and reducing the
cost of therapy. With the emergence of targeted delivery systems
and technology to block the IL-10 transcription and other rel-
evant molecules involved in the IL-10 signaling (e.g., STAT3), a
new era of molecular targeting of regulatory cytokines is on the
horizon.
ACKNOWLEDGMENTS
This work was supported by Extramural Program of the National
Institute of Allergy and Infectious Diseases (NIAID), National
Institute of Health (TMRC Grant No. P50AI074321). Authors
thank Ms. Neetu Singh and Mr. Shashi Bhushan, Research Scholar
of Department of Medicine, Banaras Hindu University for helpful
comments and suggestions in the preparation of the manuscript.
Om Prakash Singh thanks CSIR, New Delhi for providing Senior
Research Fellowship.
REFERENCES
1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol
(1996) 14:417–23. doi:10.1016/0738-081X(96)00057-0
2. World Health Organization. Eliminating Visceral Leishmaniasis: A Multi-
Pronged Approach. Available at: http://www.who.int/tdr/news/2011/
vl-elimination/en/
3. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis
worldwide and global estimates of its incidence. PLoS One (2012) 7:e35671.
doi:10.1371/journal.pone.0035671
4. Addy M, Nandy A. Ten years of kala-azar in West Bengal, part I. Did post-kala-
azar dermal leishmaniasis initiate the outbreak in 24-parganas? Bull World
Health Organ (1992) 70:341–6.
5. Bern C, Hightower AW, Chowdhury R, Ali M, Amann J, Wagatsuma Y, et al.
Risk factors for kala-azar in Bangladesh. Emerg Infect Dis (2005) 11:655–62.
doi:10.3201/eid1105.040718
6. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol (2006)
22:552–7. doi:10.1016/j.pt.2006.09.004
7. Meheus F, Boelaert M, Baltussen R, Sundar S. Costs of patient management of
visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health (2006)
11:1715–24. doi:10.1111/j.1365-3156.2006.01732.x
8. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Micro-
biol Rev (2006) 19:111–26. doi:10.1128/CMR.19.1.111-126.2006
9. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of
pentavalent antimony in visceral leishmaniasis in India: report from the center
of the Indian epidemic. Clin Infect Dis (2000) 31:1104–7. doi:10.1086/318121
10. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K. Relapse of visceral
leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med
Hyg (2009) 80:580–2.
11. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharma-
cother (2005) 6:2821–9. doi:10.1517/14656566.6.16.2821
12. Jha TK. Drug unresponsiveness & combination therapy for kala-azar. Indian
J Med Res (2006) 123:389–98.
13. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposo-
mal amphotericin B for visceral leishmaniasis in India. N Engl J Med (2010)
11:504–12. doi:10.1056/NEJMoa0903627
14. Sundar S, Singh A. What steps can be taken to counter the increasing failure of
miltefosine to treat visceral leishmaniasis? Expert Rev Anti Infect Ther (2013)
11:117–9. doi:10.1586/eri.12.170
15. Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, et al. Efficacy of
miltefosine in the treatment of visceral leishmaniasis in India after a decade of
use. Clin Infect Dis (2012) 55:543–50. doi:10.1093/cid/cis474
16. Croft SL, Olliaro P. Leishmaniasis chemotherapy – challenges and opportu-
nities. Clin Microbiol Infect (2011) 17:1478–83. doi:10.1111/j.1469-0691.2011.
03630.x
17. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala azar
field isolates. J Infect Dis (2003) 188:600–7. doi:10.1086/377133
18. Sundar S,Chakravarty J,RaiVK,Agrawal N,Singh SP,ChauhanV,et al. Ampho-
tericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus
alternate-day infusions. Clin Infect Dis (2007) 45:556–61. doi:10.1086/520665
Frontiers in Immunology | Immunotherapies and Vaccines June 2014 | Volume 5 | Article 296 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Singh and Sundar Immunotherapy and targeted therapies in VL
19. Sundar S, Kumar K, Chakravarty J, Agrawal D, Agrawal S, Chhabra A, et al.
Cure of antimony-unresponsive Indian post-kala-azar dermal leishmania-
sis with oral miltefosine. Trans R Soc Trop Med Hyg (2006) 100:698–700.
doi:10.1016/j.trstmh.2005.09.015
20. Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R. Paromomycin:
uptake and resistance in Leishmania donovani. Mol Biochem Parasitol (2009)
164:111–7. doi:10.1016/j.molbiopara.2008.12.007
21. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paro-
momycin for visceral leishmaniasis in India. N Engl J Med (2007) 356:2571–81.
doi:10.1056/NEJMoa066536
22. Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis.
Expert Opin Investig Drugs (2008) 17:787–94. doi:10.1517/13543784.17.5.787
23. Das VN, Ranjan A, Sinha AN, Verma N, Lal CS, Gupta AK, et al. A randomized
clinical trial of low dosage combination of pentamidine and allopurinol in
the treatment of antimony unresponsive cases of visceral leishmaniasis. J Assoc
Physicians India (2001) 49:609–13.
24. Das VN, Siddiqui NA, Pandey K, Singh VP, Topno RK, Singh D, et al. A con-
trolled, randomized nonblinded clinical trial to assess the efficacy of ampho-
tericin B deoxycholate as compared to pentamidine for the treatment of anti-
mony unresponsive visceral leishmaniasis cases in Bihar, India. Ther Clin Risk
Manag (2009) 5:117–24. doi:10.2147/TCRM.S3581
25. Das A, Ali N. Vaccine development against Leishmania donovani. Front
Immunol (2012) 3:99. doi:10.3389/fimmu.2012.00099
26. Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S. Cytokine responses to
novel antigens in an Indian population living in an area endemic for visceral
leishmaniasis. PLoS Negl Trop Dis (2012) 6:e1874. doi:10.1371/journal.pntd.
0001874
27. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol
(2002) 20:197–216. doi:10.1146/annurev.immunol.20.083001.084359
28. Sacks D, Noben-Trauth N. The immunology of susceptibility and resis-
tance to Leishmania major in mice. Nat Rev Immunol (2002) 2:845–58.
doi:10.1038/nri933
29. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM,
et al. Interleukin 10 production correlates with pathology in human Leishma-
nia donovani infections. J Clin Invest (1993) 92:324–9. doi:10.1172/JCI116570
30. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, et al.
In vivo cytokine profiles in patients with kala-azar. Marked elevation of
both interleukin-10 and interferon-gamma. J Clin Invest (1993) 91:1644–8.
doi:10.1172/JCI116372
31. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. Splenic cytokine
responses in Indian kala-azar before and after treatment. J Infect Dis (1998)
177:815–8. doi:10.1086/517817
32. Bhattacharya P, Ali N. Involvement and interactions of different immune cells
and their cytokines in human visceral leishmaniasis. Rev Soc Bras Med Trop
(2013) 46:128–34. doi:10.1590/0037-8682-0022-2012
33. Cummings HE, Tuladhar R, Satoskar A. Cytokines and their STATs in cuta-
neous and visceral leishmaniasis. J Biomed Biotechnol (2010) 2010:294389.
doi:10.1155/2010/294389
34. Basu A, Chakrabarti G, Saha A, Bandyopadhyay S. Modulation of CD11C+
splenic dendritic cell functions in murine visceral leishmaniasis: correla-
tion with parasite replication in the spleen. Immunology (2000) 99:305–13.
doi:10.1046/j.1365-2567.2000.00939.x
35. Schwarz T, Remer KA, Nahrendorf W, Masic A, Siewe L, Müller W, et al.
T cell-derived IL-10 determines leishmaniasis disease outcome and is sup-
pressed by a dendritic cell based vaccine. PLoS Pathog (2013) 9:e1003476.
doi:10.1371/journal.ppat.1003476
36. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman
RL, et al. Interleukin-12 restores interferon-gamma production and cyto-
toxic responses in visceral leishmaniasis. J Infect Dis (1996) 173:1515–8.
doi:10.1093/infdis/173.6.1515
37. Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH,
et al. IL-12 enhances Th1-type responses in human Leishmania donovani infec-
tions. J Immunol (1995) 154:4623–9.
38. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identi-
fication and purification of natural killer cell stimulatory factor (NKSF), a
cytokine with multiple biologic effects on human lymphocytes. J Exp Med
(1989) 170(3):827–45. doi:10.1084/jem.170.3.827
39. Scharton TM, Scott P. Natural killer cells are a source of interferon gamma
that drives differentiation of CD4+ T cell subsets and induces early resistance
to Leishmania major in mice. J Exp Med (1993) 178:567–77. doi:10.1084/jem.
178.2.567
40. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol
Today (1993) 14(7):335–8. doi:10.1016/0167-5699(93)90230-I
41. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant
interleukin 12 cures mice infected with Leishmania major. J Exp Med (1993)
177:1505–9. doi:10.1084/jem.177.5.1505
42. Murray HW,Hariprashad J, Coffman RL. Behavior of visceral Leishmania dono-
vani in an experimentally induced T helper cell 2 (Th2)-associated response
model. J Exp Med (1997) 185:867–74. doi:10.1084/jem.185.5.867
43. Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, et al. Dendritic
cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are
a potent vaccine in a murine model of an intracellular infection. J Immunol
(1999) 163:3890–7.
44. Alexander CE, Kaye PM, Engwerda CR. CD95 is required for the early con-
trol of parasite burden in the liver of Leishmania donovani-infected mice. Eur
J Immunol (2001) 31:1199–210. doi:10.1002/1521-4141(200104)31:4<1199:
:AID-IMMU1199>3.0.CO;2-6
45. De Almeida Silva L, Romero HD, Prata A, Costa RT, Nascimento E, Carvalho SF,
et al. Immunologic tests in patients after clinical cure of visceral leishmaniasis.
Am J Trop Med Hyg (2006) 75:739–43.
46. Hailu A. Pre- and post-treatment antibody levels in visceral leishmania-
sis. Trans R Soc Trop Med Hyg (1990) 84:673–5. doi:10.1016/0035-9203(90)
90141-Z
47. Gidwani K, Picado A, Ostyn B, Singh SP, Kumar R, Khanal B, et al. Persistence
of Leishmania donovani antibodies in past visceral leishmaniasis cases in India.
Clin Vaccine Immunol (2010) 18:346–8. doi:10.1128/CVI.00473-10
48. Hoerauf A, Solbach W, Lohoff M, Rollinghoff M. The Xid defect determines
an improved clinical course of murine leishmaniasis in susceptible mice. Int
Immunol (1994) 6:1117–24. doi:10.1093/intimm/6.8.1117
49. Hasker E, Malaviya P, Gidwani K, Picado A, Ostyn B, Kansal S, et al. Strong
association between serological status and probability of progression to clin-
ical visceral leishmaniasis in prospective cohort studies in India and Nepal.
PLoS Negl Trop Dis (2014) 8(1):e2657. doi:10.1371/journal.pntd.0002657
50. Bhattacharyya T, Bowes DE, El-Safi S, Sundar S, Falconar AK, Singh OP,
et al. Significantly lower anti-Leishmania IgG responses in Sudanese ver-
sus Indian visceral leishmaniasis. PLoS Negl Trop Dis (2014) 8(2):e2675.
doi:10.1371/journal.pntd.0002675
51. El-On J. Current status and perspectives of the immunotherapy of leishmani-
asis. Isr Med Assoc J (2009) 11:623–8.
52. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a
systemic intracellular infection: accelerated response using interferon-gamma
in visceral leishmaniasis. J Infect Dis (1995) 171:992–6. doi:10.1093/infdis/171.
4.992
53. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al.
Treatment of visceral leishmaniasis with pentavalent antimony and interferon
gamma. N Engl J Med (1990) 322:16–21. doi:10.1056/NEJM199001043220104
54. Almeida RP, Brito J, Machado PL, De Jesus AR, Schriefer A, Guimarães LH,
et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF
and antimonials. Am J Trop Med Hyg (2005) 73:79–81.
55. Mayrink W, Botelho AC, Magalhães PA, Batista SM, Lima Ade O, Genaro O,
et al. Immunotherapy, immunochemotherapy, and chemotherapy for Ameri-
can cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop (2006) 39:14–21.
doi:10.1590/S0037-86822006000100003
56. Badaro R, Lobo I, Munos A, Netto EM, Modabber F, Campos-Neto A, et al.
Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis (2006)
194:1151–9. doi:10.1086/507708
57. Machado-Pinto J, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber
F, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial
using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int
J Dermatol (2002) 41:73–8. doi:10.1046/j.1365-4362.2002.01336.x
58. García Bustos MF, Barrio AB, Parodi Ramoneda CM, Ramos F, Mora MC, Con-
vit J, et al. Immunological correlates of cure in the first American cutaneous
leishmaniasis patient treated by immunotherapy in Argentina. A case report.
Invest Clin (2013) 52:365–75.
www.frontiersin.org June 2014 | Volume 5 | Article 296 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Singh and Sundar Immunotherapy and targeted therapies in VL
59. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas
A, et al. Role of imiquimod and parenteral meglumine antimoniate in the ini-
tial treatment of cutaneous leishmaniasis. Clin Infect Dis (2007) 44:1549–54.
doi:10.1086/518172
60. Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW.
Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of
antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg (1993)
48:666–9.
61. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE,
et al. Immunochemotherapy of persistent post-kala-azar dermal leishmania-
sis: a novel approach to treatment. Trans R Soc Trop Med Hyg (2008) 102:58–63.
doi:10.1016/j.trstmh.2007.08.006
62. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE,
Khatami A, et al. Imiquimod in combination with meglumine antimoniate
for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch
Dermatol (2006) 142:1575–9. doi:10.1001/archderm.142.12.1575
63. Sergiev VP, Shuikina EE, Kuznetsov VP, Beliaev DL, Fediainova IE, Norbadalov
MT, et al. The use of leukinferon in treating zoonotic cutaneous leishmaniasis.
2. Patient treatment. Med Parazitol (Mosk) (1993) (1):42–3.
64. Convit J, Ulrich M, Zerpa O, Borges R, Aranzazu N, Valera M, et al.
Immunotherapy of American cutaneous leishmaniasis in Venezuela during
the period 1990-99. Trans R Soc Trop Med Hyg (2003) 97:469–72. doi:10.1016/
S0035-9203(03)90093-9
65. O’Daly JA, Spinetti HM, Gleason J, Rodríguez MB. Clinical and immunolog-
ical analysis of cutaneous leishmaniasis before and after different treatments.
J Parasitol Res (2013) 2013:657016. doi:10.1155/2013/657016
66. Convit J, Ulrich M, Polegre MA, Avila A, Rodríguez N, Mazzedo MI,
et al. Therapy of Venezuelan patients with severe mucocutaneous or early
lesions of diffuse cutaneous leishmaniasis with a vaccine containing pas-
teurized Leishmania promastigotes and bacillus Calmette-Guerin: prelimi-
nary report. Mem Inst Oswaldo Cruz (2004) 99:57–62. doi:10.1590/S0074-
02762004000100010
67. Laskay T, van Zandbergen G, Solbach W. Neutrophil granulocytes as host
cells and transport vehicles for intracellular pathogens: apoptosis as infection-
promoting factor. Immunobiology (2008) 213:183–91. doi:10.1016/j.imbio.
2007.11.010
68. Aga E, Katschinski DM, van Zandbergen G, Laufs H, Hansen B, Müller K,
et al. Inhibition of the spontaneous apoptosis of neutrophil granulocytes by
the intracellular parasite Leishmania major. J Immunol (2002) 169:898–905.
doi:10.4049/jimmunol.169.2.898
69. Laufs H, Müller K, Fleischer J, Reiling N, Jahnke N, Jensenius JC, et al. Intra-
cellular survival of Leishmania major in neutrophil granulocytes after uptake
in the absence of heat-labile serum factors. Infect Immun (2002) 70:826–35.
doi:10.1128/IAI.70.2.826-835.2002
70. Saha P, Bhattacharjee S, Sarkar A, Manna A, Majumder S, Chatterjee M. Berber-
ine chloride mediates its anti-leishmanial activity via differential regulation
of the mitogen activated protein kinase pathway in macrophages. PLoS One
(2011) 6:e18467. doi:10.1371/journal.pone.0018467
71. Muniz-Junqueira MI, de Paula-Coelho VN. Meglumine antimonate directly
increases phagocytosis, superoxide anion and TNF-alpha production, but
only via TNF-alpha it indirectly increases nitric oxide production by phago-
cytes of healthy individuals, in vitro. Int Immunopharmacol (2008) 8:1633–8.
doi:10.1016/j.intimp.2008.07.011
72. Shadab M, Ali N. Evasion of host defence by Leishmania donovani: subversion
of signaling pathways. Mol Biol Int (2011) 2011:343961. doi:10.4061/2011/
343961
73. Oghumu S, Gupta G, Snider HM, Varikuti S, Terrazas CA, Papenfuss TL, et al.
STAT4 is critical for immunity but not for antileishmanial activity of antimoni-
als in experimental visceral leishmaniasis. Eur J Immunol (2013) 44(2):450–9.
doi:10.1002/eji.201343477
74. Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D. Splenic accu-
mulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regu-
latory T cells in human visceral leishmaniasis. J Exp Med (2007) 204:805–17.
doi:10.1084/jem.20061141
75. Peters N, Sacks D. Immune privilege in sites of chronic infection: Leishmania
and regulatory T cells. Immunol Rev (2006) 213:159–79. doi:10.1111/j.1600-
065X.2006.00432.x
76. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which Leish-
mania parasites can escape the host immune response: a signaling point of
view. Clin Microbiol Rev (2005) 18:293–305. doi:10.1128/CMR.18.2.293-305.
2005
77. Brandonisio O, Spinelli R, Pepe M. Dendritic cells in Leishmania infection.
Microbes Infect (2004) 6:1402–9. doi:10.1016/j.micinf.2004.10.004
78. Joshi T, Rodriguez S, Perovic V, Cockburn IA, Stager S. B7-H1 blockade
increases survival of dysfunctional CD8 (+) T cells and confers protection
against Leishmania donovani infections. PLoS Pathog (2009) 5(5):e1000431.
doi:10.1371/journal.ppat.1000431
79. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL, Heinzel FP. Mod-
ulation of T-cell costimulation as immunotherapy or immunochemother-
apy in experimental visceral leishmaniasis. Infect Immun (2003) 71:6453–62.
doi:10.1128/IAI.71.11.6453-6462.2003
80. Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X, et al.
Determinants of response to interleukin-10 receptor blockade immunother-
apy in experimental visceral leishmaniasis. J Infect Dis (2003) 188:458–64.
doi:10.1086/376510
81. Sundar S, Murray HW. Effect of treatment with interferon-gamma alone in
visceral leishmaniasis. J Infect Dis (1995) 172:1627–9. doi:10.1093/infdis/172.
6.1627
82. Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J, et al.
Antagonizing deactivating cytokines to enhance host defense and chemother-
apy in experimental visceral leishmaniasis. Infect Immun (2005) 73:3903–11.
doi:10.1128/IAI.73.7.3903-3911.2005
83. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10
and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683–765.
doi:10.1146/annurev.immunol.19.1.683
84. Murphy ML,Wille U,Villegas EN, Hunter CA, Farrell JP. IL-10 mediates suscep-
tibility to Leishmania donovani infection. Eur J Immunol (2001) 31:2848–56.
doi:10.1002/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T
85. Murray HW. Interleukin 10 receptor blockade – pentavalent antimony treat-
ment in experimental visceral leishmaniasis. Acta Trop (2005) 93:295–301.
doi:10.1016/j.actatropica.2004.11.008
86. Murray HW, Brooks EB, DeVecchio JL, Heinzel FP. Immunoenhancement com-
bined with amphotericin B as treatment for experimental visceral leishmani-
asis. Antimicrob Agents Chemother (2003) 47:2513–7. doi:10.1128/AAC.47.8.
2513-2517.2003
87. Nylen S, Sacks D. Interleukin-10 and the pathogenesis of human visceral leish-
maniasis. Trends Immunol (2007) 28:378–84. doi:10.1016/j.it.2007.07.004
88. Ansari NA, Kumar R, Gautam S, Nylén S, Singh OP, Sundar S, et al. IL-27 and
IL-21 are associated with T cell IL-10 responses in human visceral leishmania-
sis. J Immunol (2011) 186:3977–85. doi:10.4049/jimmunol.1003588
89. Gautam S, Kumar R, Maurya R, Nylén S, Ansari N, Rai M, et al. IL-10
neutralization promotes parasite clearance in splenic aspirate cells from
patients with visceral leishmaniasis. J Infect Dis (2011) 204:1134–7. doi:10.
1093/infdis/jir461
90. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(-)Foxp3(-)
Th1 cells are the source of IL-10-mediated immune suppression in chronic
cutaneous leishmaniasis. J Exp Med (2007) 204:285–97. doi:10.1084/jem.
20061886
91. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ reg-
ulatory T cells control Leishmania major persistence and immunity. Nature
(2002) 420:502–7. doi:10.1038/nature01152
92. Holaday BJ. Role of CD8+ T cells in endogenous interleukin-10 secretion asso-
ciated with visceral leishmaniasis. Mem Inst Oswaldo Cruz (2000) 95:217–20.
doi:10.1590/S0074-02762000000200013
93. Singh OP, Gidwani K, Kumar R, Nylén S, Jones SL, Boelaert M, et al. Reassess-
ment of immune correlates in human visceral leishmaniasis as defined by
cytokine release in whole blood. Clin Vaccine Immunol (2012) 19:961–6.
doi:10.1128/CVI.00143-12
94. Singh OP, Sundar S. Whole blood assay and visceral leishmaniasis: challenges
and promises. Immunobiology (2014) 219:323–8. doi:10.1016/j.imbio.2014.01.
005
95. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG. Restora-
tion of IFN-gamma production and lymphocyte proliferation in visceral leish-
maniasis. J Immunol (1994) 152:5949–56.
96. Moll H. Dendritic cells and host resistance to infection. Cell Microbiol (2003)
5(8):493–500. doi:10.1046/j.1462-5822.2003.00291.x
97. Colmenares M, Corbi AL, Turco SJ, Rivas L. The dendritic cell
receptor DC-SIGN discriminates among species and life cycle forms of
Frontiers in Immunology | Immunotherapies and Vaccines June 2014 | Volume 5 | Article 296 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Singh and Sundar Immunotherapy and targeted therapies in VL
Leishmania. J Immunol (2004) 172:1186–90. doi:10.4049/jimmunol.172.2.
1186
98. Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic
cell-based immunotherapy combined with antimony-based chemotherapy
cures established murine visceral leishmaniasis. J Immunol (2003) 170:5625–9.
doi:10.4049/jimmunol.170.11.5625
99. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, et al.
Cost-effectiveness analysis of combination therapies for visceral leishma-
niasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 4(9):e818.
doi:10.1371/journal.pntd.0000818
100. Bryceson A. A policy for leishmaniasis with respect to the prevention and con-
trol of drug resistance. Trop Med Int Health (2001) 6:928–34. doi:10.1046/j.
1365-3156.2001.00795.x
101. Davis AJ, Murray HW, Handman E. Drugs against leishmaniasis: a synergy of
technology and partnerships. Trends Parasitol (2004) 20:73–6. doi:10.1016/j.
pt.2003.11.006
102. Smith AC, Yardley V, Rhodes J, Croft SL. Activity of the novel immunomodula-
tory compound tucaresol against experimental visceral leishmaniasis. Antimi-
crob Agents Chemother (2000) 44:1494–8. doi:10.1128/AAC.44.6.1494-1498.
2000
103. Sundar S, Chatterjee M. Visceral leishmaniasis – current therapeutic modali-
ties. Indian J Med Res (2006) 123:345–52.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 03 January 2014; accepted: 07 June 2014; published online: 26 June 2014.
Citation: Singh OP and Sundar S (2014) Immunotherapy and targeted therapies in
treatment of visceral leishmaniasis: current status and future prospects. Front. Immunol.
5:296. doi: 10.3389/fimmu.2014.00296
This article was submitted to Immunotherapies and Vaccines, a section of the journal
Frontiers in Immunology.
Copyright © 2014 Singh and Sundar. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org June 2014 | Volume 5 | Article 296 | 9
